Exit
2026 MaTOS Breast | Faculty PDF Access
Translational Science of Aberrant Signal Transduction in Cancer
Therapeutic Strategies Targeting Phosphatidylinositol 3- Kinases
Therapeutic Strategies Targeting and Sequencing Serine/Threonine-Specific AKT Kinase
Future Directions Exploiting the PI3K/AKT Pathway
Therapeutic Opportunities in Tumor Immune Microenvironments
Immunotherapy Recent Updates in Breast Cancer
Breast Cancer Vaccine Strategies
Bispecific Antibodies in the Treatment of Breast Cancer
Regulation of Gene Transcription by Estrogen Receptor Containing Protein Complexes
Mechanisms of Endocrine Resistance
Orally Bioavailable Selective Estrogen Receptor Degrading Agents: Are They All the Same?
Novel Targeted Agents to Amplify or Reverse Endocrine Resistance
Agonism and Antagonism of the Androgen Receptor in Breast Cancer
Exercise and Diet: Impact on Cancer Under Cutting Edge Trials in BC
Promising New ADC Targets in Breast Cancer in the Clinic
Incorporating HER2 Targeted ADCS into the Treatment of HER2+ Breast Cancer: Early, Later or Late?
Phase I Investigation Beyond 3 + 3 Study Designs
Integration of Biomarker Research into Clinical Trials
Window of Opportunity and Neoadjuvant Study Designs as a Clinical Laboratory in Breast Cancer Research
MRD ctDNA Assays are a Useful Adjunct in the Diagnosis and Treatment of Early Breast Cancer
MRD ctDNA Measurements Are Not Ready for Prime Time in Treatment and Monitoring of Early Breast Cancer in 2026
SERENA-6 is the Wave of the Future: Therapeutic Interruption of Drug Resistance Clones in Metastatic Breast Cancer
Potential Pitfalls of Changing Therapy Based on Molecular Evidence of Emerging Resistance
Bespoke Quantitative ctDNA Assays to Monitor Progression of Disease
Inciting an Abscopal Effect Against Breast Cancer
The Rise of Precision Oncology and Biomarker-Driven Care in Breast Cancer (Non-CE)
ADC design beyond Deruxtecans – antibody conjugation, novel linkers and drugs (Non-CE)
Patient Selection for Radiotherapy De-Escalation
FLASH-RT: Theoretical Rationale and Clinical Update
Breast Surgery 2026 and Beyond: Less is More?
Strategies for Sequencing ADCs in HER2 Negative Breast Cancer: Current Data and Future Strategies
Finish Course
You need to enroll in this course to view this chapter
Mechanisms of Endocrine Resistance
Purchase for $100,000.00
0% Course Complete
Mechanisms of Endocrine Resistance Attachments
100%
Page
1
of ?
/?
Go to:
Go
Loading PDF...
